Floatz logo

js212

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Shanghai Junshi Bioscience Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations cohort.

Asset / SponsorPhaseRating
js111
Shanghai Junshi Bioscience Co., Ltd.
Phase 2B
js212 for
Shanghai Junshi Bioscience Co., Ltd.
Phase 2CCC

Same molecule, other indications

js212 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Advanced Malignant Solid TumorsDormant
CCC
Indicative ·
51 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →